KOCHI: To treat non-alcoholic fatty liver disease, the Central Marine Fisheries Research Institute (CMFRI) in this city has developed a nutraceutical product using specific seaweeds (NAFLD). The product, known as CadalminTM LivCure extract, is a special combination of 100 percent natural bioactive compounds derived from seaweeds using environmentally friendly green technology to enhance liver function.
The CMFRI has created nutraceuticals to fight a series of lifestyle disorders, including type 2 diabetes, arthritis, cholesterol, hypertension, hypothyroidism, and osteoporosis, as well as to boost immunity. This is the seventh product of its kind made from marine creatures. These nutraceuticals include one green mussel supplement and eight items made from seaweeds.
The product's study was overseen by Kajal Chakraborty, Principal Scientist of the Marine Biotechnology, Fish Nutrition and Health Division of the CMFRI. Chakraborty said that the nutraceutical product was developed using the bioactive pharmacophore leads from seaweeds.
"Pre-clinical studies revealed that LivCure extract had the potential to block a number of target enzymes and receptors linked to dyslipidemia and the pathogenesis of NAFLD. This enhances liver function, lessens fatty material disposition, and keeps other liver/lipid parameters within clinically acceptable ranges ", he said, adding that - "It has been demonstrated that prolonged oral use of this medication does not cause systemic or overall organ toxicity. The technology will soon be licenced out to individuals in the pharmaceutical sector for the purpose of commercial nutraceutical production."
"Due to their potential for use in medicine, seaweeds are frequently referred to as the miracle plants of the ocean. Due to its ability to protect against a variety of chronic diseases, this marine macro flora is currently receiving a lot of attention in the nutraceutical industries. The CMFRI has received significant national recognition as a result of its ongoing, intensive research on the extraction of bioactive compounds from seaweeds.
New innovative technology diagnoses heart failure in record time
Study finds OTC treatment can be life-threatening
ICRS needs to keep pace with changing times: Mandaviya
